Sign up for the email list
Thank you for providing a training for Mitchell/Thames Academy. Each time I see one of your presentations I learn something new, a sign of an excellent... Stacey A. Torpey LPC, NCC Mitchell College
FDA Approves Lamictal XR for Monotherapy04/27/2011
RESEARCH TRIANGLE PARK, N.C., April 25, 2011-- GlaxoSmithKline (GSK) announced that the U.S. Food and Drug Administration (FDA) has approved Lamictal® XR™ (lamotrigine) Extended-Release Tablets for conversion to monotherapy in patients 13 years and older with partial seizures taking one antiepileptic drug. This is a new indication for Lamictal XR, which is already approved as add-on treatment for partial seizures and primary generalized tonic-clonic seizures in patients in this age group. Safety and effectiveness of Lamictal XR have not been established as initial monotherapy or for simultaneous conversion to monotherapy from two or more concomitant AEDs.
Source: PR Newswire
Reviewed by Epilepsy Foundation Professional Advisory Board Member Brian Alldredge, PHARM.D.
Back To All News